Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH03018
REVIEW
Contents Vol 1(2)

HIV in prison: what are the risks and what can be done?

M. E. Hellard A B and C. K. Aitken A
+ Author Affiliations
- Author Affiliations

A Epidemiology and Social Research Program, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Vic. 3004, Australia.

B Author for correspondence; email: hellard@burnet.edu.au

Sexual Health 1(2) 107-113 https://doi.org/10.1071/SH03018
Submitted: 1 December 2003  Accepted: 23 April 2004   Published: 24 June 2004

Abstract

Prisons are recognised worldwide as important sites for transmission of blood-borne viruses (BBVs). There are two reasons why transmission risks in prison are higher than in the community. First, in most western countries, many prison entrants have histories of injecting drug use, and thus already have high prevalences of BBVs. Second, the lack or under-supply of preventive measures (such as clean needle and syringes or condoms) in most prisons, combined with extreme social conditions, creates extra opportunities for BBV transmission. HIV prevalence in prisoners in more developed countries ranges from 0.2% in Australia to over 10% in some European nations. There are case reports of HIV being transmitted by sharing injecting equipment and sexual activity. Tattooing has been reported as a risk factor for the transmission of BBVs in prison. Access to condoms and needle and syringe programmes in prisons is extremely limited, despite success when they have been introduced. The vast majority of prison inmates are incarcerated for only a few months before returning to the community, thus they are, over the long term, more appropriately regarded as ‘citizens’ than ‘prisoners’. Public health policy must involve all sections of the community, including prison inmates, if we are to reduce transmission of HIV and other BBVs.

Additional keywords: blood-borne viruses, injecting drugs, sexual transmission.


References


[1] Crofts N , Thompson SC , Kaldor J . Epidemiology of hepatitis C virus. Technical report series. Communicable Diseases Intelligence. Canberra: Commonwealth Department of Health and Aged Care; 1999.

[2] Statistics ABO . Prisoners in Australia. Available online at: http://www.abs.gov.au/Ausstats/abs@.nsf/lookupMF [Accessed 7 November 2003].

[3] Butler TG,  Dolan KA,  Ferson MJ,  McGuinness LM,  Brown PR,  Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. MJA 1997; 166(3): 127–30.
| PubMed |

[4] Hellard M , Hocking J , Crofts N . The prevention and transmission of hepatitis C virus in prison. In: Proceedings. 14th International Conference on the Reduction of Drug Related Harm, 2003. Changmai, Thailand: International Harm Reduction Association; 2003 p. 135.

[5] Rotily M,  Delorme C,  Obadia Y,  Escaffre N,  Galinier-Pujol A. Survey of French prison found that injecting drug use and tattooing occurred. BMJ 1998; 316(7133): 777.
| PubMed |

[6] Harris RM,  Sharps PW,  Allen K,  Anderson EJ,  Soeken K,  Rohatas A. The interrelationship between violence, HIV/AIDS, and drug use in incarcerated women. J Assoc Nurses AIDS Care 2003; 14(1): 27–40.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Braithwaite RL,  Arriola KRJ. Male prisoners and HIV prevention: a call for action ignored. Am J Public Health 2003; 93(5): 759–63.
| PubMed |

[8] Spaulding A,  Stephenson B,  Macalino G,  Ruby W,  Clarke JG,  Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. HIV/AIDS 2002; 35 305–312.
| Crossref | GoogleScholarGoogle Scholar |

[9] HIV/AIDS. Viral hepatitis and sexually transmissible infections in Australia: annual surveillance report. Darlinghurst, NSW: National Centre in HIV Epidemiology and Clinical Research; 2002.

[10] McDonald AM,  Ryan JW,  Brown PR,  Manners CJ,  Falconer AD,  Kinnear RC, et al. HIV prevalence at reception into Australian prisons, 1991–1997. MJA 1999; 171(1): 18–21.
| PubMed |

[11] Rotily M,  Galinier-Pujol A,  Obadia Y,  Moatti J,  Toubiana P,  Vernay-Vaisse C, et al. HIV testing, HIV infection and associated risk factors among inmates in south-eastern French prisons. AIDS 1994; 8(9): 1341–4.
| PubMed |

[12] Rotily M,  Weilandt C,  Bird SM,  Kall K,  Van Haastrecht HJA,  Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons — a multicentre pilot study. Eur J Public Health 2001; 11(3): 243–50.
| PubMed |

[13] Allwright S,  Bradley F,  Long J,  Barry J,  Thornton L,  Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000; 321(7253): 78–82.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[14] Long J,  Allwright S,  Barry J,  Reynolds SR,  Thornton L,  Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ 2001; 323(7323): 1209–13.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[15] Ford PM,  Pearson M,  Sankar-Mistry P,  Stevenson T,  Bell D,  Austin J. HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen’s University HIV Prison Study Group. QJM 2000; 93(2): 113–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[16] Godin G,  Gagnon H,  Alary M,  Noel L,  Morissette MR. Correctional officers’ intention of accepting or refusing to make HIV preventive tools accessible to inmates. AIDS Educ Prev 2001; 13(5): 462–73.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[17] Dean-Gaitor HD,  Fleming PL. Epidemiology of AIDS in incarcerated persons in the United States, 1994–1996. AIDS 1999; 13(17): 2429–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[18] Maruschak LM. HIV in prisons and jails, 1999. NCJ 2001; 2–11.


[19] Maruschak LM . HIV in prisons, 2000. Washington, DC: Bureau of Justice Statistics; 2002.

[20] Ruiz JD,  Molitor F,  Plagenhoef JA. Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999. AIDS 2002; 16(16): 2236–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[21] Dolan K,  Wodak A,  Hall W,  Gaughwin M,  Rae F. HIV risk behaviour of IDUs before, during and after imprisonment in New South Wales. Addict Res 1996; 4(2): 151–60.


[22] Taylor A,  Goldberg D,  Emslie J,  Wrench J,  Gruer L,  Cameron S, et al. Outbreak of HIV infection in a Scottish prison. BMJ 1995; 310 289–92.
| PubMed |

[23] Krebs CP,  Simmons M. Intraprison HIV Transmission: an Assessment of whether it occurs, how it occurs, and who is at risk. AIDS Education & Prevention 2002; 14(SuppB): 53–64.
| Crossref | GoogleScholarGoogle Scholar |

[24] Horsburgh CR,  Jarvis JQ,  McArther T,  Ignacio T,  Stock P. Seroconversion to human immunodeficiency virus in prison inmates. Am J Public Health 1990; 80(2): 209–10.
| PubMed |

[25] Dolan KA,  Wodak A. HIV transmission in a prison system in an Australian State. MJA 1999; 171(1): 14–7.
| PubMed |

[26] Thaisri H,  Lerwitworapong J,  Vongsheree S,  Sawanpanyalert P,  Chadbanchachai C,  Rojanawiwat A, et al. HIV infection and risk factors among Bangkok prisons, Thailand: a prospective cohort study. BMC Infect Dis 2003; 3(25): 20.
| PubMed |

[27] Dolan K,  Wodak A,  Hall W. HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. Drug Alcohol Rev 1999; 18 139–43.
| Crossref | GoogleScholarGoogle Scholar |

[28] Levy MH. Australian prisons are still health risks. MJA 1999; 171 7.
| PubMed |

[29] Shewan D,  Macpherson A,  Reid MM,  Davies JB. Patterns of injecting and sharing in a scottish prison. Drug Alcohol Depend 1995; 39(3): 237–43.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[30] Koulierakis G,  Agrafiotis D,  Gnardellis C,  Power KG. Injecting drug use amongst inmates in Greek prisons. Addict Res 1999; 7(3): 193–212.


[31] Ehrmann T. Community based organizations and HIV prevention for incarcerated populations: three HIV prevention program models. AIDS Educ Prev 2002; 14 75–84.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[32] Frost L,  Tchertkov V. Prisoner risk taking in the Russian Federation. AIDS Educ Prev 2002; 15(4): 7–23.
| Crossref | GoogleScholarGoogle Scholar |

[33] Buavirat A,  Page-Shafer K,  van Griensven GJP,  Mandel JS,  Evans J,  Chuaratanaphong J, et al. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ 2003; 326 308–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[34] Choopanya K,  Jarlais DCD,  Vanichseni S,  Kitayaporn D,  Mock PA,  Raktham S, et al. Incareration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr 2002; 29(1): 86–93.
| PubMed |

[35] Vlahov D,  Nelson KE,  Quinn TC,  Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993; 9(5): 566–9.
| PubMed |

[36] Stark K,  Bienzle U,  Vonk R,  Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997; 26(6): 1359–66.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[37] Stark K,  Muller R. HIV prevalence and risk behaviour in injecting drug users in Berlin. Forensic Sci Int 1993; 62(1–2): 73–81.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[38] Hammett TM , Harmon P , Maruschak LM . US Department of Justice; 1999. 1996–1997 Update: HIV/AIDS, STDs, and TB in correctional facilities, issues and practises. Washington, DC: US Department of Justice 1999. pp. 1–74.

[R39] Anonymous, (2000) HIV prevalence and risk behaviour in injecting drug users in Berlin.

[40] May JP,  Williams EL. Acceptability of condom availability in a U.S. jail. AIDS Educ Prev 2002; 14 85–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[41] Saum CA,  Surratt HL,  Inciardi JA,  Bennett RE. Sex in prison: exploring the myths and realities. Prison J 1995; 75(4): 413–30.


[42] Robinson D , Mirabelli L . Summary of findings of the 1995 CSC national inmate survey. Ottowa Correctional Service of Canada; 1996.

[43] Struckman-Johnson C,  Struckman-Johnson D,  Rucker L,  Bumby K,  Donaldson S. Sexual coercion reported by men and women in prison. J Sex Res 1996; 33(1): 67–76.


[44] Struckman-Johnson C,  Struckman-Johnson D. Sexual coercion rates in seven midwestern prison facilities for men. Prison J 2000; 80(4): 379–90.


[45] Makkai T,  McAllister I. Prevalence of tattooing and body piercing in the Australian community. Commun Dis Intell 2001; 25 67–72.
| PubMed |

[46] Crofts N,  Thompson S,  Wale E,  Hernberger F. Risk behaviours for blood-borne viruses in a Victorian prison. ANZJCrim 1996; 29 20–8.


[47] Awofeso N,  Williams C. Branded - tattooing in prisons. Trop Doct 2000; 30(3): 186–7.
| PubMed |

[48] Awofeso N. Jaggers in the pokey: understanding tattooing in prisons and reacting rationally to it. Aust Health Rev 2002; 25(2): 162–9.
| PubMed |

[49] Post JJ,  Dolan KA,  Whybin LR,  Carter IW,  Haber PS,  Lloyd AR. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. MJA 2001; 174(4): 183–4.
| PubMed |

[50] Crofts N,  Stewart T,  Hearne P,  Xin YP,  Breschkin AM,  Locarnini SA. Spread of blood borne viruses among Australian prison entrants. BMJ 1995; 310 285–288.
| PubMed |

[51] Dolan KA,  Wodak AD,  Hall WD. A bleach program for inmates in NSW: an HIV prevention strategy. Aust N Z J Public Health 1998; 22(7): 838–40.
| PubMed |

[52] Samuel MC,  Doherty PM,  Bulterys M,  Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico. Epidemiol Infect 2001; 127 475–84.
| PubMed |

[53] Haber PS,  Parsons SJ,  Harper SE,  While PA,  Rawlinson WD,  Lloyd A. Transmission of hepatitis C within Australian prisons. MJA 1999; 171 31–3.
| PubMed |

[54] Hall W,  Ward J,  Mattick R. Methadone maintenance treatment in prisons: the New South Wales Experience. Drug Alcohol Rev 1993; 12 193–203.


[55] Dolan K,  Hall W,  Wodak A. Methadone maintenance reduces injecting in prison. BMJ 1996; 312(7039): 1162.
| PubMed |

[56] Dolan K,  Rutter S,  Wodak A. Prison-based syringe exchange programmes: a review of international research and development. Addiction 2003; 98 153–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[57] Veit F . A report on the study of syringe exchanges in European prisons. Melbourne: Burnet Institute/The Winston Curchill Memorial Trust of Australia; 2001.

[58] Rutter S , Dolan K , Wodak A , Heilpern H . Prison-based syringe exchange programs. A review of international research and program development. Sydney: National Drug and Alcohol Research Centre; 2001.

[59] Shewan D , Davies JB . Drug use and prisons: an international perspective. Amsterdam: Harwood Academic Publishers.

[60] Dolan KA,  Rutter SA,  Wodak AD,  Hall WD,  Maher LS,  Dixon DC. Is a syringe exchange feasible in a prison setting? MJA 1996; 164(8): 508.
| PubMed |

[61] Godin G,  Alary M,  Morissette M,  Noel L.. Correctional officers and prevention of HIV transmission among prisoners. Can HIV/AIDS Pol & Law Rev 2001; 6(1/2): 70–1.